To investigate the efficacy and safety of taurine supplementation for alleviating symptoms and improving outcomes in individuals affected by long COVID (PASC), particularly focusing on those with persistent symptoms.
Key Findings:
Taurine is upregulated in plasma during COVID-19 convalescence and correlates negatively with long COVID symptoms.
Taurine supplementation has shown potential benefits in reducing inflammation, enhancing bioenergetics, and countering cellular senescence.
No clinical trials have directly examined taurine supplementation in PASC patients, highlighting a significant gap in research.
Interpretation:
Taurine may offer therapeutic benefits for individuals suffering from long COVID by targeting underlying mechanisms such as chronic inflammation and cellular aging, underscoring the need for further research.
Limitations:
Lack of direct clinical trials on taurine supplementation specifically for PASC.
Potential heterogeneity in trial results due to varying study designs and populations, as well as possible biases in the included studies.
Conclusion:
Taurine supplementation warrants further investigation as a potential treatment for alleviating symptoms of long COVID, given its biological roles and observed correlations with symptom severity, emphasizing the urgency for clinical trials.
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.
